Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in AMLX — Amylyx Pharmaceuticals, Inc.

CIK 1423053 MIAMI, FL
Back to AMLX Full portfolio

Position in AMLX

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$5,720,293
+$1,553,080 QoQ
Shares Held
411,532
+19.3% QoQ
Ownership
0.370%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2022
17 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in AMLX Over Time

Shares Held

Position Value (USD)

Derivatives in AMLX

reported options exposure · as of Mar 31, 2026
CallValue
$629,670
CallShares
45,300
PutValue
$177,920
PutShares
12,800

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - Specialty & Generic

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $928,363,116 across 59 Drug Manufacturers - Specialty & Generic names. AMLX ranks #22 (0.6% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 UTHR
UNITED THERAPEUTICS Corp
 360,643 $213,854,086
2 INDV
Indivior Pharmaceuticals, Inc.
 3,574,044 $108,936,860
3 ELAN
Elanco Animal Health Inc
 4,387,127 $104,983,948
4 ALKS
Alkermes plc.
 2,241,584 $79,262,409
5 SUPN
Supernus Pharmaceuticals, Inc.
 1,493,446 $77,196,223
6 ZTS
Zoetis Inc.
 501,011 $59,224,510
7 VTRS
Viatris Inc
 3,993,155 $53,947,523
8 KNSA
Kiniksa Pharmaceuticals International, plc
 474,750 $22,859,212

All Filings in AMLX

Export CSV
47 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $177,920 12,800
2026-03-31 $629,670 45,300
2026-03-31 $5,720,293 411,532
2025-12-31 $1,351,752 111,900
2025-12-31 $4,167,213 344,968
2025-09-30 $530,010 39,000
2025-09-30 $1,333,179 98,100
2025-09-30 $3,189,205 234,673
2025-06-30 $285,886 44,600
2025-06-30 $7,967,162 1,242,927
2025-03-31 $124,962 35,300
2025-03-31 $98,412 27,800
2025-03-31 $9,762,526 2,757,776
2024-12-31 $7,449,260 1,970,704
2024-12-31 $510,300 135,000
2024-12-31 $470,988 124,600
2024-09-30 $289,332 89,300
2024-09-30 $6,154,573 1,899,560
2024-09-30 $520,668 160,700
2024-06-30 $2,555,154 1,344,818
2024-06-30 $131,100 69,000
2024-06-30 $265,430 139,700
2024-03-31 $1,288,792 453,800
2024-03-31 $1,358,088 478,200
2024-03-31 $3,778,289 1,330,384
2023-12-31 $32,985,826 2,240,885
2023-12-31 $3,344,384 227,200
2023-12-31 $1,968,064 133,700
2023-09-30 $2,092,833 114,300
2023-09-30 $22,465,344 1,226,944
2023-09-30 $2,620,161 143,100
2023-06-30 $3,584,934 166,200
2023-06-30 $1,166,937 54,100
2023-06-30 $17,543,419 813,325
2023-03-31 $6,716,101 228,906
2023-03-31 $2,904,660 99,000
2023-03-31 $2,863,584 97,600
2022-12-31 $2,097,170 56,757
2022-12-31 $3,270,075 88,500
2022-12-31 $1,910,315 51,700
2022-09-30 $22,712,264 806,830
2022-09-30 $6,685,625 237,500
2022-09-30 $11,589,355 411,700
2022-06-30 $1,519,614 78,900
2022-06-30 $14,529,935 754,410
2022-06-30 $4,820,778 250,300
2022-03-31 $6,446,022 501,636

Report a Problem

Category
Description
Email (optional, for follow-up)